
DOGE's next phase
Presented by
Driving the Day
WHAT'S NEXT FOR DOGE? The Department of Government Efficiency is continuing its work — even without its leader, Elon Musk, albeit now in a quieter way, POLITICO's Robin Bravender, Danny Nguyen and Sophia Cai report.
'DOGE is at work. They're not going away,' the Office of Management and Budget's director, Russ Vought, told Fox News recently. 'I talk to them every single day.'
Yet, in recent weeks, some agency leaders, including those at HHS, have publicly broken with DOGE directives, a phenomenon that could become more widespread as Musk steps away from his role. Today is his last day with the White House.
In April, leaders of the National Institutes of Health rolled back DOGE directives that instructed staffers to send weekly emails outlining their productivity and limited purchases and travel on company cards, according to messages obtained by POLITICO.
That prompted some staffers to suspect the agency's recently confirmed director, Dr. Jay Bhattacharya, and perhaps others at HHS, were willing to break with Musk and DOGE.
Bhattacharya portrayed himself as powerless against DOGE's mass workforce terminations because they landed the same day he joined the agency in April, though he said he would reinstate some procurement staffers who shouldn't have been terminated.
The movement at the NIH and other HHS offices weeks after illustrates a more complicated portrait.
Since the start of the second Trump administration, at least six DOGE officials with NIH credentials have descended on the agency, and some have slashed scientific research grants and conducted staff reorganizations, terminations and other purported cost-cutting measures, according to an NIH staffer familiar with the matter and granted anonymity out of concerns they would face retribution.
Bhattacharya and other HHS leaders have done little to stave off those deeper cuts, said the NIH staffer and another institute staffer who were granted anonymity out of fear of reprisal.
Health Secretary Robert F. Kennedy Jr. 'strongly supports DOGE's mission and views the team as a critical partner in restoring public trust in our health institutions,' said HHS spokesperson Andrew Nixon. 'Cutting waste, fraud and abuse at HHS remains a top priority.'
The White House, DOGE and Musk did not respond to requests for comment.
In July, NIH is expected to submit plans to dramatically consolidate the NIH's information technology departments, where more than a dozen teams are based in various suboffices, even as it remains unclear how much work contractors can backfill, the staffers said.
Now, employees have been charged with essentially firing each other by developing plans to slash down the IT departments, said the two staffers.
'DOGE is still hungry,' one of the NIH staffers said. 'We've still got to feed the f–ing dog.'
WELCOME TO FRIDAY PULSE. Quick housekeeping note: This is my (Chelsea's) last edition of Pulse as I am leaving POLITICO for a new opportunity. It's been a pleasure being in your inboxes each morning. Thank you for all the tips, scoops and feedback — please continue to send them to my wonderful colleague Kelly at khooper@politico.com and follow along @Kelhoops.
AROUND THE AGENCIES
STATE OF THE RIF — CDC layoffs planned for early June are being paused in the wake of a preliminary injunction, two employees at the agency, granted anonymity for fear of retribution, confirmed to POLITICO's Sophie Gardner.
CDC employees who were sent termination notices in April received an email from the agency's Office of Human Resources on Thursday, informing them that, because of a preliminary injunction, HHS 'is staying further action on any existing Reduction in Force (RIF) notices, including final separation of employees, at this time.'
The laid-off employees will remain on paid administrative leave 'or in their current employment status' until further notice, the email said.
An HHS spokesperson did not immediately respond to a request for comment.
Background: On April 1, amid a massive restructuring of HHS, around 18 percent of the CDC's workforce received termination notices. But legal challenges have complicated the reduction in force and the HHS reorganization, meaning the vast majority of those employees are still technically employed at the CDC, with most remaining on administrative leave.
Key context: On May 22, Judge Susan Illston of the federal district court in San Francisco issued a preliminary injunction that bars the administration from carrying out the reduction in force across 22 agencies — including HHS — that are defendants in the case. Federal employee unions, nonprofits and local governments are the plaintiffs.
The email sent to CDC employees cites Illston's injunction as the reason for the decision.
MAHA REPORT CORRECTED — The White House blamed 'formatting issues' for errors in the citations of the recently released Make America Healthy Again report after a media report found studies in it that do not exist.
'We have complete confidence in [Secretary Robert F. Kennedy Jr.] and his team at HHS. I understand there were some formatting issues with the MAHA report,' White House press secretary Karoline Leavitt said Thursday.
Her remarks came after NOTUS reported that seven of the sources cited in the report, which said children's health is in crisis and blamed chemicals, lack of exercise and ultraprocessed foods, don't exist.
The report now lists five of its citations as 'corrected' or 'updated,' though that doesn't include the citations NOTUS reported as false.
'Some of the hundreds of citations in the report were formatted incorrectly or mistakenly referenced something other than what was actually intended,' a White House spokesperson told Pulse. 'That said, the content of the report is fully substantiated, and there is nothing in there that cannot be backed up; we did not conjure up any facts. Report has been corrected now.'
REPORT: IMPROVE GRANT OVERSIGHT — The NIH must do a better job of providing oversight of ongoing research grants that the agency has awarded to outside entities, the Government Accountability Office said in a report released Thursday.
The report comes as the federal government slashes a number of NIH-funded grants to research institutions and universities, including those focused on diversity, equity and inclusion. HHS Secretary Robert F. Kennedy Jr. has bemoaned bureaucratic bloat at his department for failing to focus its work on the root causes of chronic disease.
According to Thursday's report, the NIH spent more than $35 billion supporting 65,000 grants to external entities in fiscal 2023.
However, the GAO found that NIH program officers, tasked with tracking recipients' progress, didn't always close out awards when recipients failed to file final reports within a year of the project's end, as required by policy.
As of Aug. 2024, nearly 1,000 final reports, or about 0.2 percent of awards made from fiscal 2014 through fiscal 2024, were missing.
Their recommendations: GAO called on the NIH to identify the cause of the missing reports, develop an informational resource on how to manage unused award money and require NIH centers to track all unused funds. The NIH agreed with all three recommendations.
In Congress
FIRST IN PULSE: ANTI-ABORTION GROUP TARGETS GOP — A major anti-abortion group will launch a monthlong campaign in June to urge Senate Republicans to keep anti-abortion language in the sweeping megabill that passed the House.
Students for Life Action plans to target 12 GOP senators who they call 'friends and sometimes foes,' the group's president, Kristan Hawkins, said in a statement, 'all of whom are expressing reluctance on the need to set aside our differences to prioritize getting abortion vendors out of our healthcare spending.'
Background: The One Big, Beautiful Bill Act narrowly passed the House this month with language in it that would eliminate Medicaid funding to Planned Parenthood. However, the bill will likely undergo major changes in the Senate when lawmakers return in June. Federal funding already can't fund abortion services.
The Republican senators being targeted by the group are:
— Shelley Moore Capito (W.Va.)— Susan Collins (Maine)— Ron Johnson (Wis.)— Mike Lee (Utah)— Mitch McConnell (Ky.)— Lisa Murkowski (Alaska)— Rand Paul (Ky.)— Rick Scott (Fla.)— Dan Sullivan (Alaska)— John Thune (S.D.)— Thom Tillis (N.C.)— Todd Young (Ind.)
Names in the News
Kevin Barstow is joining O'Melveny as a partner in its health care practice group and congressional investigations team. He was senior counsel and special assistant to the president in the Biden White House.
The Congressional Budget Office has named its panel of health advisers, who will advise the agency on its analysis of the cost of health care policy. The members are Katherine Baicker, Michael Chernew, Jeffrey Clemens, Heather Dlugolenski, Marisa Domino, Erin Fraher, Craig Garthwaite, Darrell Gaskin, John Haupert, Anne Karl, Lisa Lee, Thomas Lee, Patricia MacTaggart, David Meltzer, Sergio Santiviago, Kosali Simon, Neeraj Sood, Cori Uccello and Melanie Whittington.
WHAT WE'RE READING
NBC reports on how a new Covid variant could impact cases this summer.
POLITICO's Ruth Reader reports on a new CMMI official leading AI.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
HHS ends Biden-era COVID-19 testing program that bled taxpayers years after pandemic
FIRST ON FOX: The Department of Health and Human Services announced it is shuttering a nationwide program that offered free COVID-19 tests to community organizations, citing it bled taxpayer funds despite the pandemic's end. "With COVID-19 behaving more like the seasonal flu — rising and falling through the year — and tests widely available at retail stores nationwide, continued federal distribution is a significant waste of taxpayers' dollars," HHS told Fox News Digital Tuesday. "The COVID-19 pandemic is over and HHS is prioritizing funding projects that will deliver on President Trump's mandate to address the chronic disease epidemic and Make America Healthy Again." The government had spent more than $1 billion on the program since it was established in 2021 under the Biden administration, Fox News Digital learned. The program deployed government-purchased COVID-19 tests to community partners across the country to deliver tests at no cost to the patient. HHS cited that testing for COVID-19 now mimics seasonal flu cases, with retail shops across the country stocking their shelves with COVID tests, meaning "continued federal distribution is a significant waste of taxpayers' dollars." Doctors Warn Of 'Trifecta' Of Chronic Illnesses Plaguing Americans After Maha Report Americans who ordered tests through community partnership by 5 p.m. May 30 will still receive their order, according to HHS. Read On The Fox News App HHS is in the midst of purchasing one million newer tests that are able to differentiate between the COVID-19 virus versus the flu, which will be deployed if there are any shortfalls or emergencies with the COVID testing, Fox Digital learned. State or local health departments, as well as community organizations that have a stockpile of tests and various local health centers may still provide free tests to Americans as the program shutters, according to HHS. The COVID-19 pandemic, which tore across the country in 2020, officially ended years ago. Then-President Joe Biden declared the pandemic was "over" back in 2022, while the World Health Organization determined the pandemic officially ended by 2023. The announcement comes as the Trump administration's top health department re-focuses its direction to addressing the nation's spiraling chronic health issues, which come in the form of health issues such as rampant obesity, spikes in autism diagnoses and teenage depression. Rfk Jr's Highly Anticipated Maha Report Paints Dismal State Of Child Health, National Security Concerns President Donald Trump's Make America Healthy Again Commission, which is chaired by HHS chief Robert F. Kennedy Jr, released its anticipated report assessing chronic diseases that have gripped U.S. youth in recent years May 22. The report's findings include teenage depression nearly doubling from 2009 to 2019, more than one-in-five children over the age of six being considered obese, one-in-31 children diagnosed with autism by age 8 and childhood cancer spiking by 40% since 1975. Trump And A Healthier America Welcomed By Doctors: 'New Golden Age' "Over 40% of the roughly 73 million children (aged 0-17) in the United States have at least one chronic health condition, according to the CDC, such as asthma, allergies, obesity, autoimmune diseases, or behavioral disorders," the report stated. "Although estimates vary depending on the conditions included, all studies show an alarming increase over time." Chronic diseases have a chilling effect on national security, commission members said in a Thursday morning phone call with the media. Roughly 75% of America's youth aged 17–24 do not qualify to serve in the military due to obesity, asthma, allergies, autoimmune diseases or behavioral disorders, they said. "We now have the most obese, depressed, disabled, medicated population in the history of the world, and we cannot keep going down the same road," Food and Drug Commissioner Marty Makary said in the phone call with the media. "So this is an amazing day. I hope this marks the grand pivot from a system that is entirely reactionary to a system that will now be proactive." The MAHA report will be followed by a policy recommendation report for the federal government later this article source: HHS ends Biden-era COVID-19 testing program that bled taxpayers years after pandemic


Forbes
an hour ago
- Forbes
Access To Abortion Pill Mifepristone Could Be Threatened, Again
In this photo illustration, packages of mifepristone tablets are displayed at a family planning ... More clinic. Mifepristone is part of a two-drug regimen to induce an abortion in the first trimester of pregnancy in combination with the drug misoprostol. (Photo illustration by) The abortion pill mifepristone is in the crosshairs of politics again, as plaintiffs in several high-profile court cases together with Republican lawmakers push for restrictions. More importantly perhaps, the Food and Drug Administration is reviewing the regulation and labeling of mifepristone, a drug with a well-established safety and effectiveness record. In an unusual move, Secretary of Health and Human Services, Robert F. Kennedy Jr., issued a statement last month to the Senate Health, Education, Labor and Pensions Committee directing the FDA to 'do a complete review' of its regulations on mifepristone, a medication used in conjunction with misoprostol in two-thirds of abortions in the United States– which has been used by more than eight million people since its approval more than two decades ago. The FDA approved mifepristone in 2000 for medication abortion. Mifepristone is a drug that blocks progesterone, which is needed for a pregnancy to continue. When taken in conjunction with misoprostol, mifepristone ends early pregnancies (up to ten weeks following conception). Mifepristone can be safely administered at home when prescribed by a provider, The FDA has allowed people to take the medication outside of a clinic setting since 2021. And that same year, the FDA further eased several conditions with respect to the prescribing and sale of mifepristone. Specifically, the regulatory authority allowed for prescriptions to be issued through telemedicine visits in addition to shipments of the product by mail, as MedPage Today reported. It appears that rising numbers of abortions using prescription drugs in the past four years may be linked to the changes instituted by the FDA. In addition, the use of medication to end pregnancies could have also been triggered by the Supreme Court decision to overturn Roe v. Wade in 2022, as a Journal of the American Medical Association study describes. But it appears that besides wanting to subject mifepristone to a new FDA review, Kennedy also wishes to reinstate the in-person dispensing requirement, which would mean women must go to a clinic to obtain mifepristone. The Supreme Court preserved convenient access to mifepristone last year, throwing out a lawsuit that sought to reinstate the previous requirements. The justices' argument, however, largely hinged on questioning the physician plaintiffs' right to sue the FDA to restore conditions rather than the substance of the case. But then, earlier this year, The Hill reported that a Texas federal judge, Matthew Kacsmaryk, is allowing three Republican-led states to move forward with a lawsuit to restrict access to mifepristone. It's noteworthy that in 2023, Kacsmaryk temporarily halted FDA's approval of mifepristone altogether. In brief, it's unclear what will happen to access as cases move through the court system and findings from the review which Kennedy ordered are revealed. Mifepristone has been in use in Europe for nearly three decades with a minimal number of reported adverse events. And the drug has had a similar safety record in the U.S since its approval in 2000. Between September 2000 and December 2018, only 24 of the more than 3.7 million women who had undergone medicated abortions have died, according to the FDA. Overall, the adverse events rate is less than 1% and the drug is considered safer than, say, over-the-counter non-steroidal anti-inflammatory drugs and anti-histamines. At least 100 studies from around the world have examined the effectiveness and safety of mifepristone and misoprostol. All peer-reviewed studies concluded that the pills are a safe method for terminating a pregnancy. Yet there seems to be a non-peer-reviewed study that's at the center of a request for the FDA to assess mifepristone. It's from the conservative think tank, the Ethics and Public Policy Center. This particular study makes claims about what it views as a high rate of serious adverse events following medication abortions. Yet, the evidence from the U.S. and around the globe suggests a highly safe and effective medication. The FDA's mandate is to review the safety and efficacy of drugs based on clinical evidence. As such, the FDA is the federal authority for all pharmaceuticals distributed throughout the U.S., including mifepristone and misoprostol. And so, a series of court cases and Secretary Kennedy's request for another look at mifepristone set a potentially unsettling precedent in which the FDA's regulatory authority from past decisions is undermined. And it's not just mifepristone that's currently under renewed scrutiny. Consider, for example, that HHS is revisiting debunked theories of links between the measles, mumps and rubella vaccine and autism. The department has also spearheaded changes in COVID-19 vaccine recommendations that are not necessarily evidence-based, and inconsistent with prior and even current guidance from the Centers for Disease Control and Prevention.
Yahoo
an hour ago
- Yahoo
Musk's Neuralink Secures $650 Million for Clinical Push
Neuralink just closed a hefty $650 million Series E round, pushing its valuation past the $9 billion mark. Backed by big names like ARK Invest, Founders Fund, Sequoia Capital, QIA and Valor Equity Partners, this infusion makes it clear that investors still believe in Tesla (NASDAQ:TSLA) CEO Elon Musk's vision of braincomputer interfaces (BCIs). In more concrete terms, it means Neuralink can accelerate its clinical trialsright now, five patients with severe paralysis are already using implanted devices to control computers and smartphones with their thoughts alone. Those trials span institutions like the Barrow Neurological Institute, Miami Project to Cure Paralysis, Toronto Western Hospital and the Cleveland Clinic in Abu Dhabi. And because Neuralink is hoping to snag Breakthrough Device Designation from the FDA for its vision and speech restoration program, the clock is tickingdecisions on that usually land within 60 days. If they get it, the path to wider use becomes a lot smoother. Of course, this isn't just about bolstering medical trials. With the new capital, Neuralink can beef up manufacturing and expand its engineering teamscritical steps if it's going to compete in an emerging market for neuroprosthetics. Moreover, thanks to Musk's broader ecosystem commitment with Tesla, SpaceX, Starlink, xAI and XNeuralink has unique access to AI expertise, hardware know-how and regulatory resources. All told, the big raise and the early patient wins suggest Neuralink's bets on restoring autonomy to people with paralysis (and possibly beyond) are far from over. This article first appeared on GuruFocus. Sign in to access your portfolio